Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and deeper tumor reductions versus KEYTRUDA alone.
The update came from the Phase 2 portion of the HexAgon study, which is evaluating INBRX-106, an OX40 agonist, in combination with pembrolizumab compared with pembrolizumab alone. Lappe said the trial was modeled after KEYNOTE-048 and enrolled patients with high PD-L1 expression, defined as a combined positive score of at least 20.
